Edwards Lifesciences Corporation $EW Position Lessened by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA cut its stake in Edwards Lifesciences Corporation by 58.2%, reducing its holdings to approximately $2.08 million as of the latest SEC filing.
• Institutional investors hold 79.46% of Edwards Lifesciences' stock, with firms like AQR Capital Management and Focus Partners Advisor Solutions increasing their stakes significantly in the first quarter.
• Edwards Lifesciences reported an earnings per share (EPS) of $0.67 for the last quarter, which exceeded analyst expectations, and provided guidance for FY 2025 EPS between $2.400-2.500.

Banque Transatlantique SA lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 58.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,993 shares of the medical research company's stock after selling 43,161 shares during the period. Banque Transatlantique SA's holdings in Edwards Lifesciences were worth $2,076,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $266,000. Bank Pictet & Cie Europe AG raised its stake in Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares in the last quarter. Aptus Capital Advisors LLC raised its stake in Edwards Lifesciences by 25.8% during the fourth quarter. Aptus Capital Advisors LLC now owns 10,001 shares of the medical research company's stock valued at $740,000 after buying an additional 2,052 shares in the last quarter. Benjamin Edwards Inc. raised its stake in Edwards Lifesciences by 25.1% during the fourth quarter. Benjamin Edwards Inc. now owns 19,168 shares of the medical research company's stock valued at $1,419,000 after buying an additional 3,844 shares in the last quarter. Finally, Baker Avenue Asset Management LP acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $249,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE EW traded down $0.07 on Friday, reaching $80.89. 2,283,330 shares of the stock traded hands, compared to its average volume of 3,558,037. The company has a market cap of $47.49 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 3.90 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm's fifty day simple moving average is $78.77 and its 200 day simple moving average is $75.21. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock valued at $1,698,844 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on EW. Piper Sandler upped their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft increased their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Stifel Nicolaus increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.